Fairmount Funds Management LLC 13D and 13G filings for Oruka Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2025-03-10 7:00 pm Purchase | 2025-03-06 | 13D | Oruka Therapeutics, Inc. ORKA | Fairmount Funds Management LLC | 8,511,824 19.990% | 570,134![]() (+7.18%) | Filing |
2024-11-21 6:30 pm Purchase | 2024-11-19 | 13D | Oruka Therapeutics, Inc. ORKA | Fairmount Funds Management LLC | 7,941,690 19.990% | 17![]() (+0.00%) | Filing |
2024-09-13 4:57 pm Purchase | 2024-09-11 | 13D | Oruka Therapeutics, Inc. ORKA | Fairmount Funds Management LLC | 7,941,673 19.990% | 1,330,418![]() (+20.12%) | Filing |
2024-09-06 5:08 pm Purchase | 2024-08-29 | 13D | Oruka Therapeutics, Inc. ORKA | Fairmount Funds Management LLC | 6,611,255 19.990% | 6,611,255![]() (New Position) | Filing |